NKTR Nektar Therapeutics - Common Stock
$75,92
Precio · Ago 19, 2026
Fundamentales a fecha de Ago 14, 2026
Rango 52S
$25–$109
60% of range
Calificación del Analista
BUY
17 analysts
Precio Objetivo
$153
+102% upside
P/E (TTM)
-11.3
ROE
-500.1%
Margen de Beneficio Neto
-297.1%
Acerca de Nektar Therapeutics - Common Stock Descripción general de la empresa de Wikipedia
Nektar Therapeutics is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California. The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances, which improves drug characteristics like retention and solubility. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, etc. The company developed the world's first inhalable non-injectable insulin, Exubera, which was awarded as the bronze award by Wall Street Journal for its technological breakthrough.
Leer más
Nektar Therapeutics is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California. The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances, which improves drug characteristics like retention and solubility. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, etc. The company developed the world's first inhalable non-injectable insulin, Exubera, which was awarded as the bronze award by Wall Street Journal for its technological breakthrough.
Background
The company is engaged in developing a proprietary pipeline of drug candidates for several therapeutic areas including oncology, pain, anti-infectives, anti-viral and immunology. The company's research and development involve in small molecule and biologic drug candidates. Its drug candidate base consists of naloxegol (Movantik), a Phase III oral opioid antagonist, etirinotecan pegol, a topoisomerase inhibitor under Phase III clinical study as of 2012, NKTR 061, NKTR-181, NKTR-214, etc.
In 2013, the company was assigned a patent which was developed by the company and other four co-inventors. The products of the company is served as a supplement to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability and other areas of drugs for the patients worldwide. As of March 2014, the company had a market capitalization of $1.7 billion with an enterprise value of $1.67 billion.
As of December 2024, at a stock price-per-share of roughly $1, the market cap is roughly $171 million. Nektar underwent periods of downsizing after unsuccessful partnerships were ended with Eli Lilly in 2023 and Bristol Myers Squibb in 2022, resulting in layoffs of most company employees.
Pipeline
Etirinotecan pegol was in the phase III BEACON trial as well as in the I-SPY2 adaptive clinical trial for breast cancer in 2016. The European Medicines Agency refused a marketing authorisation in 2017.
Bempegaldesleukin (NKTR-214) is a CD122-biased immune-stimulatory cytokine, Phase I results were announced in November 2016. It is now in a phase 2 trial in combination with nivolumab for various advanced cancers.
In 2023 Nektar's partnership with Eli Lilly in development of "rezpeg" was ended. Eli Lilly claimed the drug lacked suitable efficacy, while Nektar responded that Eli Lilly had botched the analysis.
Fuente: Wikipedia (Inglés), CC BY-SA 4.0 · Ver en Wikipedia ↗
NKTR Instantánea de la Acción Precio, capitalización bursátil, P/E, BPA, ROE, deuda/capital, rango de 52 semanas
Precio
$75.92
Capitalización Bursátil
$2.24B
P/E (TTM)
-11.3
BPA (TTM)
$-9.73
Ingresos (TTM)
$55M
Rendimiento div.
—
ROE
-500.1%
Deuda/Capital
—
Rango 52S
$25 – $109
NKTR Gráfico del Precio de la Acción OHLCV diario con indicadores técnicos — desplace, amplíe y personalice su vista
Configure
Rendimiento a 10 años Tendencias de ingresos, beneficio neto, márgenes y BPA
Ingresos y Beneficio Neto
$55M
2016-12-31
→
2025-12-31
BPA
$-9.73
2016-12-31
→
2025-12-31
Flujo de caja libre
$-209M
2016-12-31
→
2025-12-31
Márgenes
-297.1%
Valoración Ratios P/E, P/S, P/B, EV/EBITDA: ¿está la acción cara o barata?
Métrica
Tendencia a 5 años
NKTR
Mediana de Pares
P/E (TTM)
-11.3
29.4
P/S (TTM) (P/V (TTM))
40.5
4.9
P/B (P/C)
24.9
6.5
Price / FCF (Precio / FCF)
-10.7
—
Rentabilidad Márgenes brutos, operativos y netos; ROE, ROA, ROIC
Métrica
Tendencia a 5 años
NKTR
Mediana de Pares
Operating Margin (Margen Operativo)
-253.7%
—
Net Profit Margin (Margen de Beneficio Neto)
-297.1%
-9.0%
ROA
-56.2%
-8.2%
ROE
-500.1%
-19.4%
ROIC
-155.8%
—
Salud financiera Deuda, liquidez, solvencia — solidez del balance general
Métrica
Tendencia a 5 años
NKTR
Mediana de Pares
Current Ratio (Ratio corriente)
5.0
3.6
Quick Ratio (Ratio Rápido)
0.3
—
Crecimiento Crecimiento de ingresos, BPA y beneficio neto: interanual, CAGR a 3 años, CAGR a 5 años
Métrica
Tendencia a 5 años
NKTR
Mediana de Pares
Revenue YoY (Ingresos interanuales)
-43.9%
—
Revenue CAGR 3Y (Ingresos CAGR 3A)
-15.7%
—
Revenue CAGR 5Y (Ingresos CAGR 5A)
-18.4%
—
Eficiencia de capital Rotación de activos, rotación de inventario, rotación de cuentas por cobrar
Métrica
Tendencia a 5 años
NKTR
Mediana de Pares
NKTR Consenso de analistas Opiniones de analistas alcistas y bajistas, precio objetivo a 12 meses, potencial alcista
COMPRA
17 analistas
- Compra fuerte 7 41,2%
- Compra 8 47,1%
- Mantener 2 11,8%
- Venta 0 0,0%
- Venta fuerte 0 0,0%
Precio objetivo a 12 meses
9 analistas · 2026-08-16
Mediana
$151.00
← Por Debajo de Todos los Objetivos
$75.92
Mín
$80.00
Máx
$192.00
Objetivo mediano
$151.00
+98,9%
Objetivo medio
$153.22
+101,8%
Historial de Ganancias EPS real vs estimado, sorpresa %, tasa de aciertos, próxima fecha de resultados
Sorpresa Media
0.21%
| Período | EPS Actual | EPS est. | Sorpresa |
|---|---|---|---|
| 30 de junio de 2026 | $-1.23 | $-2.02 | 0.79% |
| 31 de marzo de 2026 | $-1.82 | $-1.63 | -0.19% |
| 31 de diciembre de 2025 | $-1.78 | $-2.52 | 0.74% |
| 30 de septiembre de 2025 | $-1.87 | $-2.74 | 0.87% |
| 30 de junio de 2025 | $-2.95 | $-3.10 | 0.15% |
| 31 de marzo de 2025 | $-3.60 | $-2.51 | -1.1% |
Comparación de pares (subindustria GICS) Métricas clave frente a competidores del sector
| Ticker | Capitalización Bursátil | P/E | Ingresos interanuales | Margen Neto | ROE | Margen Bruto |
|---|---|---|---|---|---|---|
| NKTR | $862M | -4.3 | -43.9% | -297.1% | -500.1% | — |
| ALMS | — | -3.4 | — | -1011.8% | -61.9% | — |
| TARS | $3.48B | -51.5 | 146.7% | -14.7% | -19.7% | — |
| SUPN | $2.86B | -73.1 | 8.6% | -5.4% | -3.6% | — |
| ATAI | $223M | -1.4 | -1.9% | -48464.0% | -83.1% | — |
| TRVI | $1.61B | -39.1 | — | — | -22.4% | — |
| AMRX | — | 57.3 | 8.1% | 2.4% | -80.0% | 36.9% |
| AMLX | $1.33B | -7.9 | -77.1% | — | -61.2% | — |
| PBH | $3.33B | 15.2 | -4.3% | 17.5% | 10.2% | 54.7% |
| RAPP | $1.45B | -10.6 | — | — | -29.8% | — |
| OCUL | $2.62B | -8.5 | -18.5% | -511.9% | -55.4% | — |
Fundamentales Completos Todas las métricas por año — estado de resultados, balance general, flujo de caja
Estado de resultados 17
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $55M | $98M | $90M | $92M | $102M | $153M | $115M | $1.19B | $308M | $165M | $231M | $201M | |
| Cost of Revenue | $0 | $31M | $34M | $22M | $25M | $19M | $21M | $24M | $31M | $30M | $34M | $29M | |
| R&D Expense | $117M | $121M | $114M | $218M | $400M | $409M | $435M | $400M | $268M | $204M | $183M | $148M | |
| SG&A Expense | $69M | $77M | $77M | $92M | $123M | $105M | $99M | $81M | $52M | $44M | $43M | $41M | |
| Operating Expenses | $195M | $204M | $354M | $468M | $548M | $578M | $555M | $505M | $367M | $278M | $260M | $217M | |
| Operating Income | $-140M | $-105M | $-264M | $-376M | $-446M | $-425M | $-440M | $688M | $-60M | $-113M | $-29M | $-16M | |
| Interest Expense | · | · | · | $0 | $0 | $7M | $21M | $22M | $22M | $22M | $18M | $18M | |
| Interest Income | $10M | $14M | $19M | $7M | $3M | · | · | · | · | · | · | · | |
| Other Non-op | $361.0K | $-390.0K | $-6M | $-116.0K | $-162.0K | $18M | $46M | $38M | $5M | $2M | $2M | $814.0K | |
| Pretax Income | $-164M | $-119M | $-276M | $-365M | $-523M | $-444M | $-440M | $683M | $-96M | $-153M | $-81M | $-54M | |
| Income Tax | $-138.0K | $-239.0K | $-200.0K | $3M | $557.0K | $493.0K | $613.0K | $1M | $616.0K | $876.0K | $506.0K | $-512.0K | |
| Net Income | $-164M | $-119M | $-276M | $-368M | $-524M | $-444M | $-441M | $681M | $-97M | $-154M | $-81M | $-54M | |
| EPS (Basic) | $-9.73 | $-8.68 | $-1.45 | $-1.97 | $-2.86 | $-2.49 | $-2.52 | $4.02 | $-0.62 | $-1.10 | · | · | |
| EPS (Diluted) | $-9.73 | $-8.68 | $-1.45 | $-1.97 | $-2.86 | $-2.49 | $-2.52 | $3.78 | $-0.62 | $-1.10 | · | · | |
| Shares (Basic) | 16,870,930 | 13,710,775 | 190,001,000 | 187,138,000 | 183,298,000 | 178,581,000 | 174,993,000 | 169,600,000 | 155,953,000 | 139,596,000 | · | · | |
| Shares (Diluted) | 16,870,930 | 13,710,775 | 190,001,000 | 187,138,000 | 183,298,000 | 178,581,000 | 174,993,000 | 180,119,000 | 155,953,000 | 139,596,000 | · | · | |
| EBITDA | $-140M | $-101M | $-257M | $-364M | $-433M | $-413M | $-429M | $697M | $-47M | $-113M | $-29M | · |
Balance general 24
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $15M | $44M | $35M | $88M | $25M | $199M | $96M | $195M | $5M | $60M | $56M | $12M | |
| Short-term Investments | · | · | · | · | · | · | · | · | $291M | $329M | $253M | $225M | |
| Receivables | · | $0 | $1M | $6M | $22M | $39M | $37M | $43M | $5M | $16M | $20M | $4M | |
| Inventory | $0 | $0 | $16M | $19M | $16M | $15M | $13M | $11M | $11M | $11M | $11M | $13M | |
| Other Current Assets | $21M | $6M | $10M | $16M | $23M | $22M | $15M | $21M | $8M | $10M | $10M | $9M | |
| Current Assets | $266M | $261M | $331M | $546M | $796M | $1.14B | $1.42B | $1.44B | $327M | $426M | $350M | $288M | |
| PP&E (Net) | $2M | $3M | $19M | $32M | $61M | $60M | $66M | $49M | $47M | $66M | $71M | $70M | |
| Accum. Depreciation | · | $16M | $87M | $125M | $148M | $138M | $128M | $121M | $115M | $111M | $103M | $94M | |
| Goodwill | · | · | $0 | $77M | $77M | $77M | $77M | $77M | $77M | $77M | $77M | $77M | |
| Other Non-current Assets | $14M | $5M | $5M | $2M | $3M | $1M | $344.0K | $4M | $994.0K | $817.0K | $754.0K | $7M | |
| Total Assets | $280M | $304M | $398M | $711M | $1.12B | $1.54B | $1.98B | $2.15B | $509M | $569M | $499M | $442M | |
| Accounts Payable | $11M | $12M | $10M | $13M | $10M | $22M | $19M | $6M | $5M | $3M | $2M | $3M | |
| Accrued Liabilities | $22M | $30M | $22M | $37M | · | · | · | · | · | · | · | $6M | |
| Current Liabilities | $54M | $61M | $51M | $68M | $85M | $116M | $354M | $82M | $56M | $72M | $61M | $64M | |
| Capital Leases | $65M | $83M | $99M | $113M | $126M | $136M | $143M | $0 | · | $2M | $1M | $4M | |
| Other Non-current Liabilities | $9M | $7M | $5M | $8M | $4M | $9M | $768.0K | $10M | $6M | $7M | $10M | $15M | |
| Total Liabilities | $191M | $243M | $267M | $344M | $438M | $461M | $572M | $433M | $421M | $481M | $492M | $405M | |
| Common Stock | $2.0K | $1.0K | $19.0K | $19.0K | $19.0K | $18.0K | $17.0K | $17.0K | $15.0K | $15.0K | $13.0K | $13.0K | |
| Retained Earnings | $-3.76B | $-3.60B | $-3.48B | $-3.20B | $-2.83B | $-2.31B | $-1.86B | $-1.42B | $-2.12B | $-2.02B | $-1.87B | $-1.79B | |
| Treasury Stock | · | $3M | $0 | · | · | · | · | · | · | · | · | · | |
| AOCI | $17.0K | $61.0K | $80.0K | $-7M | $-4M | $-2M | $-1M | $-6M | $-2M | $-2M | $-2M | $-2M | |
| Stockholders' Equity | $90M | $61M | $131M | $367M | $680M | $1.08B | $1.41B | $1.72B | $88M | $88M | $6M | $36M | |
| Liabilities + Equity | $280M | $304M | $398M | $711M | $1.12B | $1.54B | $1.98B | $2.15B | $509M | $569M | $499M | $442M | |
| Shares Outstanding | 20,378,832 | 12,385,001 | 12,757,984 | 188,560,000 | 185,468,000 | 180,091,000 | 176,505,000 | 173,530,000 | 159,524,000 | 153,212,000 | 135,289,000 | 131,216,000 |
Flujo de Efectivo 14
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $4M | $7M | $12M | $13M | $12M | $11M | $9M | $13M | $13M | $11M | $13M | |
| Stock-based Comp | · | · | · | · | · | · | · | · | · | · | · | $17M | |
| Deferred Tax | $64.0K | $-10.0K | $-140.0K | $3M | $-102.0K | $-36.0K | $-21.0K | $93.0K | $35.0K | $-115.0K | $-22.0K | $-31.0K | |
| Other Non-cash | · | $-61M | $77M | $49M | $98M | $119M | $101M | $28M | $4M | · | · | · | |
| Operating Cash Flow | $-209M | $-176M | $-193M | $-304M | $-413M | $-313M | $-329M | $718M | $-80M | $-117M | $-73M | $-142M | |
| CapEx | $171.0K | $1M | $865.0K | $6M | $15M | $7M | $26M | $14M | $10M | $6M | $11M | $10M | |
| Investing Cash Flow | $-1M | $143M | $140M | $366M | $203M | $496M | $207M | $-1.38B | $-29M | $-82M | · | · | |
| Stock Repurchased | $0 | $3M | $0 | · | · | · | · | · | · | · | · | · | |
| Net Stock Activity | $0 | $-3M | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $181M | $42M | $30.0K | $2M | $36M | $-80M | $23M | $852M | $54M | $204M | · | · | |
| Net Change in Cash | $-29M | $9M | $-53M | $63M | $-174M | $103M | $-99M | $190M | $-55M | $4M | $43M | $-27M | |
| Taxes Paid | $-195.0K | $76.0K | $3M | $272.0K | $325.0K | $539.0K | $555.0K | $618.0K | $556.0K | $757.0K | $860.0K | $964.0K | |
| Free Cash Flow | $-209M | $-177M | $-193M | $-310M | $-428M | $-321M | $-355M | $704M | $-90M | $-123M | $-84M | · | |
| Levered FCF | · | · | · | $-310M | $-428M | $-327M | $-376M | $682M | $-112M | $-146M | $-103M | · |
Rentabilidad 7
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -253.7% | -106.9% | -292.6% | -408.6% | -437.8% | -278.0% | -383.9% | 57.6% | -19.4% | -68.2% | -12.7% | · | |
| Net Margin | -297.1% | -120.9% | -306.3% | -400.0% | -514.0% | -290.6% | -384.5% | 57.1% | -31.4% | -92.8% | -35.2% | · | |
| Pretax Margin | -297.3% | -121.1% | -306.5% | -396.5% | -513.5% | -290.3% | -383.9% | 57.2% | -31.2% | -92.3% | -35.0% | · | |
| EBITDA Margin | -253.7% | -102.7% | -284.8% | -395.4% | -425.0% | -269.8% | -374.3% | 58.4% | -15.3% | -68.2% | -12.7% | · | |
| ROA | -56.2% | -33.9% | -49.8% | -40.3% | -39.5% | -25.3% | -21.3% | 51.2% | -17.9% | -28.8% | -17.2% | · | |
| ROE | -500.1% | -217.0% | -190.2% | -94.5% | -70.7% | -39.5% | -30.4% | 38.9% | -109.9% | -324.7% | -379.7% | · | |
| ROIC | -155.8% | -172.9% | -201.2% | -103.5% | -65.7% | -39.5% | -31.4% | 40.0% | -68.3% | -128.8% | -459.7% | · |
Liquidez y Solvencia 3
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.0 | 4.3 | 6.5 | 8.0 | 9.3 | 9.8 | 4.0 | 17.5 | 5.8 | 5.9 | 5.7 | · | |
| Quick Ratio | 0.3 | 0.7 | 0.7 | 1.4 | 0.6 | 2.1 | 0.4 | 2.9 | 5.4 | 5.6 | 5.4 | · | |
| Interest Coverage | · | · | · | · | · | -62.1 | -20.6 | 31.9 | -2.7 | -5.0 | -1.6 | · |
Eficiencia 3
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.3 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.9 | 0.6 | 0.3 | 0.5 | · | |
| Inventory Turnover | · | 3.8 | 1.9 | 1.2 | 1.6 | 1.4 | 1.8 | 2.2 | 2.8 | 2.7 | 2.8 | · | |
| Receivables Turnover | · | 163.4 | 25.1 | 6.5 | 3.3 | 4.0 | 2.9 | 49.5 | 29.7 | 9.3 | 19.6 | · |
Tasas de Crecimiento 3
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -43.9% | 9.2% | -2.1% | -9.7% | -33.4% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -15.7% | -1.1% | -16.2% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | -18.4% | · | · | · | · | · | · | · | · | · | · | · |
Valoración (TTM) 10
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $55M | $98M | $90M | $92M | $102M | $153M | $115M | $1.19B | $308M | $165M | $231M | $201M | |
| Net Income TTM | $-164M | $-119M | $-276M | $-368M | $-524M | $-444M | $-441M | $681M | $-97M | $-154M | $-81M | $-54M | |
| Market Cap | $862M | $2.59B | $1.61B | $6.39B | $37.59B | $45.92B | $57.16B | $85.56B | $142.90B | $28.20B | $34.19B | · | |
| P/E | -4.3 | -1.6 | -5.8 | -17.2 | -70.9 | -102.4 | -128.5 | 130.4 | -1444.8 | -167.3 | -414.3 | -516.7 | |
| P/S | 15.6 | 26.3 | 17.8 | 69.4 | 368.8 | 300.3 | 498.7 | 71.7 | 464.4 | 170.5 | 148.2 | · | |
| P/B | 9.6 | 42.7 | 12.3 | 17.4 | 55.3 | 42.6 | 40.7 | 49.8 | 1627.1 | 320.0 | 5318.8 | · | |
| P / Tangible Book | 9.6 | 42.7 | 12.3 | 22.0 | 62.3 | 45.9 | · | · | · | · | · | · | |
| P / Cash Flow | -4.1 | -14.7 | -8.3 | -21.0 | -91.1 | -146.6 | -173.9 | 119.1 | -1777.1 | -241.0 | -467.9 | · | |
| P / FCF | -4.1 | -14.6 | -8.3 | -20.6 | -87.9 | -143.3 | -161.0 | 121.5 | -1586.2 | -228.5 | -405.7 | · | |
| Earnings Yield | -23.0% | -62.2% | -17.3% | -5.8% | -1.4% | -0.98% | -0.78% | 0.77% | -0.07% | -0.60% | -0.24% | -0.19% |
Estado de resultados 16
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10M | $11M | $22M | $12M | $11M | $10M | $29M | $24M | $23M | $22M | $24M | $24M | $20M | $22M | $22M | $24M | |
| Cost of Revenue | · | · | $0 | $0 | $0 | $0 | $8M | $4M | $10M | $9M | $7M | $12M | $7M | $7M | $6M | $5M | |
| R&D Expense | $39M | $36M | $30M | $27M | $30M | $30M | $29M | $35M | $30M | $27M | $30M | $24M | $30M | $30M | $35M | $34M | |
| SG&A Expense | $13M | $13M | $11M | $16M | $17M | $24M | $17M | $19M | $21M | $20M | $17M | $21M | $18M | $21M | $22M | $23M | |
| Operating Expenses | $52M | $50M | $49M | $43M | $47M | $55M | $15M | $58M | $73M | $57M | $57M | $69M | $71M | $156M | $74M | $78M | |
| Operating Income | $-42M | $-39M | $-28M | $-32M | $-36M | $-45M | $14M | $-34M | $-50M | $-35M | $-34M | $-45M | $-51M | $-135M | $-52M | $-54M | |
| Interest Income | $9M | $4M | $3M | $3M | $2M | $3M | $3M | $3M | $4M | $4M | $5M | $5M | $5M | $4M | · | · | |
| Other Non-op | $-100.0K | $-336.0K | $-44.0K | $-121.0K | $260.0K | $266.0K | $-135.0K | $-120.0K | $-36.0K | $-99.0K | $-6M | $-335.0K | $736.0K | $-301.0K | $-4M | $2M | |
| Pretax Income | $-40M | $-43M | $-43M | $-35M | $-39M | $-46M | $7M | $-37M | $-52M | $-37M | $-42M | $-46M | $-51M | $-137M | $-57M | $-59M | |
| Income Tax | $2.0K | $64.0K | $31.0K | $-33.0K | $-188.0K | $52.0K | $-259.0K | $9.0K | $46.0K | $-35.0K | $-29.0K | $-61.0K | $-47.0K | $-63.0K | $3M | $-155.0K | |
| Net Income | $-41M | $-45M | $-36M | $-36M | $-42M | $-51M | $7M | $-37M | $-52M | $-37M | $-42M | $-46M | $-51M | $-137M | $-60M | $-59M | |
| EPS (Basic) | $-1.23 | $-1.82 | $-4.67 | $-1.87 | $-2.95 | $-3.62 | $-2.07 | $-2.66 | $-3.76 | $-0.19 | $-0.21 | $-0.24 | $-0.27 | $-0.73 | $-0.32 | $-0.31 | |
| EPS (Diluted) | $-1.23 | $-1.82 | $-4.67 | $-1.87 | $-2.95 | $-3.62 | $-2.07 | $-2.66 | $-3.76 | $-0.19 | $-0.21 | $-0.24 | $-0.27 | $-0.73 | $-0.32 | $-0.31 | |
| Shares (Basic) | 33,054,865 | 24,736,066 | -227,086,936 | 18,946,559 | 14,087,307 | 14,063,402 | -208,906,454 | 13,949,851 | 13,921,378 | 194,746,000 | -378,936,000 | 190,406,000 | 189,656,000 | 188,875,000 | -373,151,000 | 187,641,000 | |
| Shares (Diluted) | 33,054,865 | 24,736,066 | -227,086,936 | 18,946,559 | 14,087,307 | 14,063,402 | -208,906,454 | 13,949,851 | 13,921,378 | 194,746,000 | -378,936,000 | 190,406,000 | 189,656,000 | 188,875,000 | -373,151,000 | 187,641,000 | |
| EBITDA | $-42M | $-39M | · | $-32M | $-36M | $-45M | · | $-34M | $-50M | $-35M | · | $-45M | $-51M | $-135M | · | $-54M |
Balance general 23
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $39M | $150M | $15M | $41M | $43M | $39M | $44M | $30M | $28M | $49M | $35M | $65M | $51M | $77M | $88M | $106M | |
| Receivables | · | · | · | · | · | · | · | $0 | $1M | $4M | $1M | $2M | $1M | $3M | $6M | $12M | |
| Inventory | · | · | $0 | · | · | · | $0 | $0 | $14M | $16M | $16M | $15M | $21M | $20M | $19M | $19M | |
| Other Current Assets | $55M | $20M | $21M | $11M | $11M | $11M | $6M | $9M | $8M | $11M | $10M | $9M | $10M | $11M | $16M | $23M | |
| Current Assets | $739M | $589M | $266M | $281M | $187M | $230M | $261M | $286M | $295M | $320M | $331M | $399M | $441M | $491M | $546M | $599M | |
| PP&E (Net) | · | · | $2M | $3M | $3M | $3M | $3M | $4M | $15M | $17M | $19M | $20M | $23M | $27M | $32M | $37M | |
| Accum. Depreciation | · | · | · | · | · | · | · | $16M | $88M | · | $87M | $88M | $108M | $111M | $125M | · | |
| Goodwill | · | · | · | · | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $77M | $77M | |
| Other Non-current Assets | $17M | $11M | $6M | $5M | $5M | $5M | $5M | $5M | $4M | $5M | $5M | $5M | $2M | $1M | $2M | $2M | |
| Total Assets | $1.10B | $763M | $280M | $301M | $208M | $256M | $304M | $308M | $343M | $396M | $398M | $442M | $494M | $562M | $711M | $781M | |
| Accounts Payable | $25M | $10M | $11M | $16M | $14M | $18M | $12M | $9M | $6M | $9M | $10M | $3M | $3M | $4M | $13M | $5M | |
| Accrued Liabilities | $23M | $25M | $22M | $29M | $35M | $31M | $30M | $32M | $30M | $24M | $22M | $30M | $29M | $37M | $37M | · | |
| Current Liabilities | $71M | $58M | $54M | $66M | $71M | $71M | $61M | $68M | $57M | $52M | $51M | $52M | $51M | $60M | $68M | $84M | |
| Capital Leases | $56M | $61M | $65M | $70M | $74M | $78M | $83M | $87M | $91M | $95M | $99M | $102M | $106M | $109M | $113M | $116M | |
| Other Non-current Liabilities | $8M | $8M | $9M | $5M | $6M | $7M | $7M | $7M | $8M | $4M | $5M | $5M | $5M | $6M | $8M | $3M | |
| Total Liabilities | $192M | $187M | $191M | $216M | $232M | $243M | $243M | $259M | $264M | $269M | $267M | $283M | $297M | $321M | $344M | $369M | |
| Common Stock | $3.0K | $3.0K | $2.0K | $2.0K | $1.0K | $19.0K | $1.0K | $19.0K | $19.0K | $19.0K | $19.0K | $19.0K | $19.0K | $19.0K | $19.0K | $19.0K | |
| Retained Earnings | $-3.85B | $-3.81B | $-3.76B | $-3.72B | $-3.69B | $-3.65B | $-3.60B | $-3.60B | $-3.57B | $-3.51B | $-3.48B | $-3.44B | $-3.39B | $-3.34B | $-3.20B | $-3.14B | |
| Treasury Stock | · | · | · | $0 | $3M | $3M | $3M | $3M | $3M | $3M | · | · | · | · | · | · | |
| AOCI | $-2M | $-1M | $17.0K | $56.0K | $-14.0K | $39.0K | $61.0K | $355.0K | $-494.0K | $-403.0K | $80.0K | $-6M | $-6M | $-6M | $-7M | $-8M | |
| Stockholders' Equity | $903M | $576M | $90M | $85M | $-24M | $14M | $61M | $49M | $80M | $127M | $131M | $159M | $197M | $241M | $367M | $412M | |
| Liabilities + Equity | $1.10B | $763M | $280M | $301M | $208M | $256M | $304M | $308M | $343M | $396M | $398M | $442M | $494M | $562M | $711M | $781M | |
| Shares Outstanding | 20,378,832 | 20,378,832 | 20,378,832 | 19,652,513 | 12,457,252 | 186,103,000 | 12,385,001 | 184,458,000 | 184,061,000 | 183,624,000 | 191,384,000 | 190,771,000 | 190,119,000 | 189,235,000 | 188,560,000 | 187,954,000 |
Flujo de Efectivo 12
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $156.0K | $151.0K | $190.0K | $196.0K | $214.0K | $426.0K | $332.0K | $993.0K | $1M | $2M | $2M | $2M | $2M | $2M | $3M | $3M | |
| Deferred Tax | · | · | · | · | · | · | $2.0K | $-31.0K | $57.0K | $-38.0K | $2M | $-15.0K | $-27.0K | $-2M | $3M | $0 | |
| Restructuring | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $17M | |
| Operating Cash Flow | $-76M | $-44M | $-65M | $-49M | $-46M | $-49M | $-46M | $-44M | $-38M | $-48M | $-47M | $-42M | $-52M | $-52M | $-58M | $-83M | |
| CapEx | $94.0K | $18.0K | $18.0K | $114.0K | $37.0K | $2.0K | $459.0K | $666.0K | $186.0K | $157.0K | $237.0K | $33.0K | $162.0K | $433.0K | $512.0K | $181.0K | |
| Investing Cash Flow | $-399M | $-351M | $372.0K | $-95M | $50M | $44M | $60M | $46M | $17M | $19M | $17M | $56M | $25M | $41M | $40M | $111M | |
| Stock Repurchased | · | · | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $3M | $0 | $0 | $0 | $0 | · | · | |
| Net Stock Activity | · | · | · | · | · | $0 | · | · | · | $-3M | · | · | · | · | · | · | |
| Financing Cash Flow | $365M | $530M | $39M | $142M | $211.0K | $7.0K | $83.0K | $13.0K | $19.0K | $42M | $12.0K | $0 | $18.0K | $0 | $103.0K | $0 | |
| Net Change in Cash | $-110M | $134M | $-26M | $-2M | $4M | $-5M | $14M | $2M | $-21M | $13M | $-30M | $14M | $-26M | $-11M | $-18M | $28M | |
| Taxes Paid | · | · | · | · | · | · | · | · | · | · | $0 | $0 | · | · | $272.0K | $-85.0K | |
| Free Cash Flow | · | $-44M | · | · | · | $-49M | · | · | · | $-48M | · | · | · | $-52M | · | · |
Rentabilidad 7
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -417.9% | -359.6% | · | -268.6% | -324.2% | -425.8% | · | -142.4% | -211.9% | -163.7% | · | -185.8% | -246.8% | -623.8% | · | -229.9% | |
| Net Margin | -401.0% | -413.4% | · | -301.3% | -372.2% | -486.4% | · | -153.6% | -222.9% | -170.1% | · | -189.8% | -249.4% | -634.5% | · | -249.9% | |
| Pretax Margin | -397.8% | -396.7% | · | -297.0% | -352.5% | -443.3% | · | -153.6% | -222.7% | -170.2% | · | -190.1% | -249.6% | -634.8% | · | -250.6% | |
| EBITDA Margin | -417.9% | -359.6% | · | -268.6% | -324.2% | -425.8% | · | -142.4% | -211.9% | -163.7% | · | -185.8% | -246.8% | -623.8% | · | -229.9% | |
| ROA | -6.2% | -8.8% | · | -11.7% | -15.1% | -15.6% | · | -9.9% | -12.5% | -7.7% | · | -7.5% | -7.5% | -17.3% | · | -5.7% | |
| ROE | -9.2% | -15.2% | · | -53.0% | -150.0% | -72.5% | · | -35.6% | -37.9% | -20.0% | · | -16.0% | -15.6% | -32.3% | · | -9.7% | |
| ROIC | -4.7% | -6.8% | · | -37.2% | 148.9% | -324.5% | · | -70.3% | -62.5% | -27.9% | · | -28.1% | -25.7% | -55.9% | · | -13.1% |
Liquidez y Solvencia 2
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.4 | 10.2 | · | 4.2 | 2.6 | 3.2 | · | 4.2 | 5.1 | 6.1 | · | 7.7 | 8.7 | 8.2 | · | 7.1 | |
| Quick Ratio | 0.6 | 2.6 | · | 0.6 | 0.6 | 0.5 | · | 0.4 | 0.5 | 1.0 | · | 1.3 | 1.0 | 1.3 | · | 1.4 |
Eficiencia 3
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.1 | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Inventory Turnover | · | · | · | · | · | · | · | 0.6 | 0.6 | 0.5 | · | 0.7 | 0.4 | 0.4 | · | 0.3 | |
| Receivables Turnover | · | · | · | · | · | · | · | 21.9 | 18.6 | 6.5 | · | 3.5 | 3.6 | 1.3 | · | 1.2 |
Valoración (TTM) 10
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $44M | $44M | · | $58M | $69M | $80M | · | $93M | $90M | $88M | · | $90M | $87M | $92M | · | $95M | |
| Net Income TTM | $-163M | $-173M | · | $-165M | $-182M | $-177M | · | $-172M | $-186M | $-271M | · | $-293M | $-406M | $-446M | · | $-454M | |
| Market Cap | $1.42B | $1.47B | · | $1.12B | $322M | $1.90B | · | $3.60B | $3.42B | $2.56B | · | $1.72B | $1.65B | $1.99B | · | $9.02B | |
| P/E | -8.9 | -7.0 | · | -7.4 | -2.7 | -1.5 | · | -2.8 | -4.2 | -9.8 | · | -5.8 | -4.0 | -4.4 | · | -0.1 | |
| P/S | 32.4 | 33.1 | · | 19.4 | 4.6 | 23.8 | · | 38.5 | 38.1 | 29.1 | · | 19.1 | 18.9 | 21.7 | · | 94.9 | |
| P/B | 1.6 | 2.5 | · | 13.1 | -13.3 | 138.2 | · | 73.6 | 43.0 | 20.2 | · | 10.8 | 8.4 | 8.2 | · | 21.9 | |
| P / Tangible Book | 1.6 | 2.5 | · | 13.1 | · | 138.2 | · | 73.6 | 43.0 | 20.2 | · | 10.8 | 8.4 | 8.2 | · | 26.9 | |
| P / Cash Flow | · | -33.1 | · | · | · | -38.7 | · | · | · | -53.5 | · | · | · | -38.3 | · | · | |
| P / FCF | · | -33.1 | · | · | · | -38.7 | · | · | · | -53.3 | · | · | · | -38.0 | · | · | |
| Earnings Yield | -11.3% | -14.3% | · | -13.6% | -37.2% | -67.2% | · | -35.1% | -24.0% | -10.2% | · | -17.2% | -24.8% | -22.7% | · | -1649.3% |
Estados Financieros Estado de resultados, balance general, flujo de caja — anual, últimos 5 años
Estado de resultados
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Ingresos | $55M | $98M | $90M | $92M | $102M |
| Margen Operativo % | -253.7% | -106.9% | -292.6% | -408.6% | -437.8% |
| Beneficio neto | $-164M | $-119M | $-276M | $-368M | $-524M |
| EPS Diluido | $-9.73 | $-8.68 | $-1.45 | $-1.97 | $-2.86 |
Balance general
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Ratio corriente | 5.0 | 4.3 | 6.5 | 8.0 | 9.3 |
| Ratio Rápido | 0.3 | 0.7 | 0.7 | 1.4 | 0.6 |
Flujo de Efectivo
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Flujo de caja libre | $-209M | $-177M | $-193M | $-310M | $-428M |
Últimas noticias Noticias recientes que mencionan a esta empresa
Mis Métricas Tu lista de seguimiento personal — filas seleccionadas de Fundamentales Completos
📊
Elige las métricas que te importan — haz clic en el ➕ junto a cualquier fila en Fundamentales Completos arriba.
Tu selección se guarda y te sigue en todos los tickers.
Propietarios institucionales (13F) 269 declarantes · $2.1B total · A fecha de 30 de junio de 2026
Instituciones que informan tener esta acción en su Formulario 13F trimestral de la SEC. Solo posiciones largas; un solo presentador puede aparecer dos veces para tramos de opciones separados. Las patas de put/call de compensación grandes suelen reflejar la creación de mercado o el inventario cubierto, no la convicción direccional.
Actividad institucional — Q2 2026 vs trimestre anterior
| Nuevas posiciones | Posiciones cerradas | Aumentado | Disminuido | Cambio neto de acciones |
|---|---|---|---|---|
| 88 (+20 vs trimestre anterior) | 41 (+9 vs trimestre anterior) | 91 (+21 vs trimestre anterior) | 48 (-8 vs trimestre anterior) | +8.5M |
Comparado con Q1 2026. Las presentaciones del Formulario 13F de la SEC vencen dentro de los 45 días posteriores al final del trimestre, más un pequeño margen para los presentadores tardíos; los trimestres que aún se encuentran dentro de esa ventana se omiten en favor del par más reciente completamente reportado.
| Institución | Valor | Acciones | % de 13F rastreadas | Tipo |
|---|---|---|---|---|
| Two Seas Capital LP | $215 868 856 | 3 092 234 | 10,35% | Acciones |
| FMR LLC | $192 088 149 | 2 751 585 | 9,21% | Acciones |
| BVF INC/IL | $166 920 946 | 2 391 075 | 8,00% | Acciones |
| VANGUARD CAPITAL MANAGEMENT LLC | $104 495 029 | 1 496 849 | 5,01% | Acciones |
| TWO SIGMA INVESTMENTS, LP | $83 911 899 | 1 202 004 | 4,02% | Acciones |
| Vestal Point Capital, LP | $69 810 000 | 1 000 000 | 3,35% | Acciones |
| STATE STREET CORP | $63 504 691 | 909 679 | 3,04% | Acciones |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $57 502 497 | 823 700 | 2,76% | Opción de compra |
| Prosight Management, LP | $56 546 100 | 810 000 | 2,71% | Acciones |
| GEODE CAPITAL MANAGEMENT, LLC | $52 759 799 | 755 586 | 2,53% | Acciones |
| ARMISTICE CAPITAL, LLC | $50 542 440 | 724 000 | 2,42% | Acciones |
| GILDER GAGNON HOWE & CO LLC | $41 946 944 | 600 873 | 2,01% | Acciones |
| MILLENNIUM MANAGEMENT LLC | $33 377 557 | 478 120 | 1,60% | Acciones |
| BRAIDWELL LP | $33 063 203 | 473 617 | 1,59% | Acciones |
| Sofinnova Investments, Inc. | $32 933 775 | 471 763 | 1,58% | Acciones |
| Woodline Partners LP | $32 871 784 | 470 875 | 1,58% | Acciones |
| ORBIMED ADVISORS LLC | $32 485 804 | 465 346 | 1,56% | Acciones |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $27 540 045 | 394 500 | 1,32% | Opción de venta |
| EMERALD ADVISERS, LLC | $27 236 930 | 390 158 | 1,31% | Acciones |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $24 331 577 | 348 540 | 1,17% | Acciones |
| DAFNA Capital Management LLC | $22 226 108 | 318 380 | 1,07% | Acciones |
| Deep Track Capital, LP | $20 943 000 | 300 000 | 1,00% | Acciones |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $19 893 826 | 284 971 | 0,95% | Acciones |
| 22NW, LP | $19 624 638 | 281 115 | 0,94% | Acciones |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $19 475 384 | 278 977 | 0,93% | Acciones |
| PRIMECAP MANAGEMENT CO/CA/ | $19 047 658 | 272 850 | 0,91% | Acciones |
| Nearwater Capital Markets, Ltd | $18 255 315 | 261 500 | 0,88% | Acciones |
| BARCLAYS PLC | $17 968 815 | 257 396 | 0,86% | Acciones |
| EMERALD MUTUAL FUND ADVISERS TRUST | $17 842 528 | 255 587 | 0,86% | Acciones |
| ADAR1 Capital Management, LLC | $17 046 485 | 244 184 | 0,82% | Acciones |
| Creek Drive Management Group LLC | $16 963 830 | 243 000 | 0,81% | Acciones |
| SEVEN GRAND MANAGERS, LLC | $16 754 400 | 240 000 | 0,80% | Acciones |
| VANGUARD FIDUCIARY TRUST CO | $16 724 731 | 239 575 | 0,80% | Acciones |
| NORGES BANK | $15 030 093 | 215 300 | 0,72% | Acciones |
| Bronte Capital Management Pty Ltd. | $13 852 678 | 198 434 | 0,66% | Acciones |
| TWO SIGMA ADVISERS, LP | $13 039 744 | 308 414 | 0,63% | Acciones |
| CITADEL ADVISORS LLC | $12 251 655 | 175 500 | 0,59% | Opción de venta |
| GREAT POINT PARTNERS LLC | $12 216 750 | 175 000 | 0,59% | Acciones |
| Caption Management, LLC | $11 944 491 | 171 100 | 0,57% | Opción de compra |
| MILLENNIUM MANAGEMENT LLC | $11 867 700 | 170 000 | 0,57% | Opción de compra |
| CITADEL ADVISORS LLC | $11 434 878 | 163 800 | 0,55% | Opción de compra |
| AMERIPRISE FINANCIAL INC | $11 050 085 | 158 288 | 0,53% | Acciones |
| Quinn Opportunity Partners LLC | $10 686 236 | 153 076 | 0,51% | Acciones |
| GOLDMAN SACHS GROUP INC | $10 011 801 | 143 415 | 0,48% | Acciones |
| Rhenman & Partners Asset Management AB | $9 860 662 | 141 250 | 0,47% | Acciones |
| Qube Research & Technologies Ltd | $9 111 671 | 130 521 | 0,44% | Acciones |
| LMR Partners LLP | $9 075 300 | 130 000 | 0,44% | Opción de venta |
| Soleus Capital Management, L.P. | $8 960 951 | 128 362 | 0,43% | Acciones |
| Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. | $8 570 364 | 122 767 | 0,41% | Acciones |
| Stonepine Capital Management, LLC | $8 422 856 | 120 654 | 0,40% | Acciones |
| SummitTX Capital, L.P. | $7 883 923 | 112 934 | 0,38% | Acciones |
| APEIRON CAPITAL Ltd | $7 429 948 | 106 431 | 0,36% | Acciones |
| CITIGROUP INC | $7 034 824 | 100 771 | 0,34% | Acciones |
| ING GROEP NV | $6 981 000 | 100 000 | 0,33% | Acciones |
| LMR Partners LLP | $6 981 000 | 100 000 | 0,33% | Acciones |
| Susquehanna Portfolio Strategies, LLC | $6 685 704 | 95 770 | 0,32% | Acciones |
| Militia Capital Management LLC | $6 282 900 | 90 000 | 0,30% | Acciones |
| ACT CAPITAL MANAGEMENT, LLC | $6 234 033 | 89 300 | 0,30% | Acciones |
| Tetragon Partners GP Ltd | $6 073 191 | 86 996 | 0,29% | Acciones |
| READYSTATE ASSET MANAGEMENT LP | $5 941 529 | 85 110 | 0,28% | Acciones |
| Birchview Capital, LP | $5 654 610 | 81 000 | 0,27% | Acciones |
| BlackRock, Inc. | $5 444 412 | 77 989 | 0,26% | Acciones |
| GROUP ONE TRADING LLC | $4 912 600 | 70 371 | 0,24% | Acciones |
| ALGERT GLOBAL LLC | $4 686 345 | 67 130 | 0,22% | Acciones |
| Moody Aldrich Partners LLC | $4 477 264 | 64 135 | 0,21% | Acciones |
| WOLVERINE TRADING, LLC | $4 330 620 | 73 500 | 0,21% | Opción de venta |
| Swiss National Bank | $4 300 296 | 61 600 | 0,21% | Acciones |
| F/m Investments LLC | $4 229 439 | 60 585 | 0,20% | Acciones |
| BANK OF AMERICA CORP /DE/ | $4 227 764 | 60 561 | 0,20% | Acciones |
| ExodusPoint Capital Management, LP | $4 084 374 | 58 507 | 0,20% | Acciones |
| Trexquant Investment LP | $3 956 831 | 56 680 | 0,19% | Acciones |
| K2 PRINCIPAL FUND, L.P. | $3 522 962 | 50 465 | 0,17% | Acciones |
| WOLVERINE TRADING, LLC | $3 403 101 | 57 758 | 0,16% | Acciones |
| RHUMBLINE ADVISERS | $3 008 381 | 43 094 | 0,14% | Acciones |
| MORGAN STANLEY | $2 943 050 | 42 158 | 0,14% | Acciones |
| Voleon Capital Management LP | $2 850 901 | 40 838 | 0,14% | Acciones |
| Anson Funds Management LP | $2 829 748 | 40 535 | 0,14% | Acciones |
| Atom Investors LP | $2 828 631 | 40 519 | 0,14% | Acciones |
| WOLVERINE TRADING, LLC | $2 792 808 | 47 400 | 0,13% | Opción de compra |
| Burkehill Global Management, LP | $2 792 400 | 40 000 | 0,13% | Acciones |
| NOMURA HOLDINGS INC | $2 792 400 | 40 000 | 0,13% | Opción de venta |
| IRIDIAN ASSET MANAGEMENT LLC/CT | $2 708 768 | 38 802 | 0,13% | Acciones |
| NOMURA HOLDINGS INC | $2 698 645 | 38 657 | 0,13% | Acciones |
| Jefferies Financial Group Inc. | $2 664 299 | 38 165 | 0,13% | Acciones |
| ALLIANCEBERNSTEIN L.P. | $2 590 200 | 36 000 | 0,12% | Acciones |
| Connor, Clark & Lunn Investment Management Ltd. | $2 575 780 | 36 897 | 0,12% | Acciones |
| ALPS ADVISORS INC | $2 386 664 | 34 188 | 0,11% | Acciones |
| FRED ALGER MANAGEMENT, LLC | $2 350 712 | 33 673 | 0,11% | Acciones |
| TUDOR INVESTMENT CORP ET AL | $2 345 616 | 33 600 | 0,11% | Opción de compra |
| Bank of New York Mellon Corp | $2 306 522 | 33 040 | 0,11% | Acciones |
| Ghisallo Capital Management LLC | $2 233 920 | 32 000 | 0,11% | Acciones |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $2 063 670 | 28 682 | 0,10% | Acciones |
| Blackstone Inc. | $2 002 011 | 28 678 | 0,10% | Acciones |
| KVP Capital Advisors, LP | $1 877 889 | 26 900 | 0,09% | Acciones |
| Ishara Investments LP | $1 860 437 | 26 650 | 0,09% | Acciones |
| Erste Asset Management GmbH | $1 830 920 | 28 000 | 0,09% | Acciones |
| Caption Management, LLC | $1 822 041 | 26 100 | 0,09% | Opción de venta |
| WINTON GROUP Ltd | $1 808 079 | 25 900 | 0,09% | Acciones |
| K2 PRINCIPAL FUND, L.P. | $1 745 250 | 25 000 | 0,08% | Opción de compra |
| Empowered Funds, LLC | $1 636 416 | 23 441 | 0,08% | Acciones |
Informantes de la empresa 40 insiders · 20 directivos · 18 consejeros
| Insider | Rol | Última actividad | Acciones en propiedad | Compras 12m | Ventas 12m | Neto 12m |
|---|---|---|---|---|---|---|
| Howard W Robin | President & CEO | 24 de julio de 2026 A | 55 045 | 0 | 20 | $-2 224 055 |
| Jillian B. Thomsen | Chief Financial Officer | 16 de febrero de 2023 S | 313 497 | 0 | 0 | $0 |
| Gil M Labrucherie | SVP, COO & CFO | 16 de mayo de 2022 S | 312 905 | 0 | 0 | $0 |
| Timothy Harkness | SVP & Chief Financial Officer | 23 de agosto de 2007 A | — | 0 | 0 | $0 |
| Louis Drapeau | Sr. VP Finance, CFO | 14 de mayo de 2007 A | 6 000 | 0 | 0 | $0 |
| Milton J Harris | President of Nektar AL | 4 de marzo de 2004 S | 743 904 | 0 | 0 | $0 |
| John Nicholson | SVP & Chief Operating Officer | 16 de agosto de 2019 S | 162 759 | 0 | 0 | $0 |
| Bharat M Chowrira | Chief Operating Officer | 1 de febrero de 2010 A | — | 0 | 0 | $0 |
| Jonathan Zalevsky | Chief R&D Officer | 24 de julio de 2026 A | 9 756 | 0 | 12 | $-1 052 364 |
| Mark Andrew Wilson | Chief Legal Officer | 21 de noviembre de 2025 A | 21 585 | 0 | 2 | $-52 171 |
| John Northcott | SVP & Chief Commercial Officer | 16 de mayo de 2022 S | 223 210 | 0 | 0 | $0 |
| Stephen K Doberstein | SVP & Chief Scientific Officer | 5 de septiembre de 2019 P | 107 668 | 0 | 0 | $0 |
| Maninder Hora | SVP Pharma Dev & Mfg Ops | 16 de mayo de 2019 S | 94 694 | 0 | 0 | $0 |
| Ivan P. Gergel | SVP & Chief Medical Officer | 15 de noviembre de 2017 A | 56 553 | 0 | 0 | $0 |
| Robert Medve | SVP & Chief Medical Officer | 5 de febrero de 2014 A | — | 0 | 0 | $0 |
| Rinko Ghosh | Chief Business Officer | 6 de febrero de 2013 A | 9 753 | 0 | 0 | $0 |
| Randall W Moreadith | SVP Drug Development | 23 de febrero de 2009 A | — | 0 | 0 | $0 |
| John Stuart Patton | Chief Scientific Officer | 14 de noviembre de 2008 M | 313 880 | 0 | 0 | $0 |
| Nevan C Elam | SVP & Head of Pulmonary Bus | 25 de febrero de 2008 A | 1 400 | 0 | 0 | $0 |
| David Johnston | SVP, Research & Development | 14 de mayo de 2007 D | 6 600 | 0 | 0 | $0 |
| Diana Brainard | Consejero | 30 de septiembre de 2025 A | 28 560 | 0 | 0 | $0 |
| Jeffrey Robert Ajer | Consejero | 30 de septiembre de 2025 A | 34 153 | 0 | 0 | $0 |
| Robert Chess | Consejero | 30 de septiembre de 2025 A | 255 273 | 0 | 0 | $0 |
| Scott R Greer | Consejero | 30 de septiembre de 2025 A | 303 574 | 0 | 0 | $0 |
| Roy A Whitfield | Consejero | 30 de septiembre de 2025 A | 216 250 | 0 | 0 | $0 |
| Myriam Curet | Consejero | 19 de septiembre de 2023 A | 27 418 | 0 | 0 | $0 |
| Karin Eastham | Consejero | 16 de septiembre de 2022 A | 23 233 | 0 | 0 | $0 |
| Lutz Lingnau | Consejero | 22 de septiembre de 2020 A | 35 800 | 0 | 0 | $0 |
| Christopher A Kuebler | Consejero | 27 de septiembre de 2018 A | 45 250 | 0 | 0 | $0 |
| Dennis L Winger | Consejero | 21 de agosto de 2018 M | 42 750 | 0 | 0 | $0 |
| Joseph J Krivulka | Consejero | 19 de septiembre de 2017 A | 82 000 | 0 | 0 | $0 |
| Susan Wang | Consejero | 20 de noviembre de 2015 M | 20 000 | 0 | 0 | $0 |
| BROWN MICHAEL A/CA | Consejero | 15 de septiembre de 2009 A | 10 000 | 0 | 0 | $0 |
| Hoyoung Huh | Consejero | 2 de diciembre de 2008 A | — | 0 | 0 | $0 |
| Irwin Lerner | Consejero | 2 de diciembre de 2008 A | 10 000 | 0 | 0 | $0 |
| James B Glavin | Consejero | 4 de septiembre de 2003 A | — | 0 | 0 | $0 |
| Masuoka K. Lorianne | — | 8 de febrero de 2011 A | — | 0 | 0 | $0 |
| Ajit Gill | President & CEO | 23 de marzo de 2006 S | 87 991 | 0 | 0 | $0 |
| Ajay Bansal | — | 10 de marzo de 2006 S | 5 166 | 0 | 0 | $0 |
| Melvin Perelman | — | 2 de septiembre de 2004 A | — | 0 | 0 | $0 |
Informantes de las presentaciones SEC Form 3/4/5; neto = solo P/S de mercado abierto
Activistas y propietarios del %+ 5 1 tenencia
Inversores que presentaron el Anexo 13D de la SEC — propiedad beneficiosa superior al % 5 con la intención de influir en el emisor (participaciones activistas, campañas de la junta directiva, M&A). Cada fila muestra el estado conocido más reciente de la posición de ese declarante.
| Declarante | Presentado | Participación | Estado | Propósito | Presentación |
|---|---|---|---|---|---|
| Nektar Therapeutics ( | 22 de agosto de 2005 | — | Presentación inicial | M&A / venta | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Propiedad de ETFs Mantenido por 28 ETFs
El peso refleja solo las tenencias directas de acciones (N-PORT); los fondos apalancados o basados en derivados pueden tener exposición adicional a swaps no mostrada.
| Fondo | Ponderación | Unidades | A fecha de | Fuente |
|---|---|---|---|---|
| LFSC · RBB Fund, Inc. | 3,14% | 50 876 NS | 31 de mayo de 2026 | N-PORT |
| SPIT · RBB Fund, Inc. | 3,11% | 10 455 NS | 30 de abril de 2026 | N-PORT |
| PILL · Direxion Shares ETF Trust | 1,55% | 2 353 NS | 30 de abril de 2026 | N-PORT |
| BBC · ETFis Series Trust I | 1,15% | 5 045 NS | 30 de abril de 2026 | N-PORT |
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,58% | 1 726 SH | 8 de agosto de 2026 | Diario |
| IHE · iShares Trust | 0,55% | 120 730 SH | 8 de agosto de 2026 | Diario |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,16% | 59 612 SH | 8 de agosto de 2026 | Diario |
| IWO · iShares Trust | 0,14% | 278 376 SH | 8 de agosto de 2026 | Diario |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,13% | 33 135 SH | 8 de agosto de 2026 | Diario |
| TMFX · RBB Fund, Inc. | 0,09% | 455 NS | 31 de mayo de 2026 | N-PORT |
| IWM · iShares Trust | 0,08% | 877 973 SH | 8 de agosto de 2026 | Diario |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,07% | 198 365 SH | 8 de agosto de 2026 | Diario |
| ISCV · iShares Trust | 0,07% | 6 414 SH | 8 de agosto de 2026 | Diario |
| SCHA · SCHWAB STRATEGIC TRUST | 0,04% | 151 830 NS | 31 de mayo de 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0,03% | 11 131 NS | 30 de abril de 2026 | N-PORT |
| ISCB · iShares Trust | 0,03% | 1 294 SH | 8 de agosto de 2026 | Diario |
| VXF · VANGUARD INDEX FUNDS | 0,03% | 387 471 SH | 8 de agosto de 2026 | Diario |
| VHT · VANGUARD WORLD FUND | 0,03% | 92 340 SH | 8 de agosto de 2026 | Diario |
| WSML · iShares Trust | 0,02% | 1 887 SH | 8 de agosto de 2026 | Diario |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,02% | 3 096 SH | 8 de agosto de 2026 | Diario |
| IWN · iShares Trust | 0,02% | 32 466 SH | 8 de agosto de 2026 | Diario |
| ONEQ · Fidelity Commonwealth Trust | 0,00% | 6 903 NS | 31 de mayo de 2026 | N-PORT |
| ITOT · iShares Trust | 0,00% | 48 124 SH | 8 de agosto de 2026 | Diario |
| IWV · iShares Trust | 0,00% | 9 139 SH | 8 de agosto de 2026 | Diario |
| TILT · FlexShares Trust | 0,00% | 770 NS | 30 de abril de 2026 | N-PORT |
| SCHB · SCHWAB STRATEGIC TRUST | 0,00% | 18 540 NS | 31 de mayo de 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 1 075 430 SH | 8 de agosto de 2026 | Diario |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 2 837 SH | 8 de agosto de 2026 | Diario |